newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears

  • IGC Pharma received Canadian Patent No. 3,095,729 for IGC-AD1, an investigational oral therapy for agitation in Alzheimer's disease.
  • The patent covers the composition for treating CNS disorders & protects IGC-AD1 across all three North American markets alongside U.S. & Mexican patents.
  • IGC-AD1 is now protected by 5 granted patents globally with 10 additional applications pending.
  • The Phase 2 CALMA trial for IGC-AD1 completed enrollment in September 2026 & is currently in its final dosing period.
  • Topline results from the CALMA trial are expected following database lock & unblinding.
  • IGC-AD1 is an oral liquid designed to address neuroinflammation, CB1 receptor signaling, & neurotransmitter regulation.
  • CEO Ram Mukunda stated that strong patent protection supports long-term commercial value & aims to attract major pharmaceutical partners.
  • IGC Pharma leverages AI to accelerate drug discovery & optimize clinical trials for Alzheimer's & metabolic disorders.